Browse NOS3

Summary
SymbolNOS3
Namenitric oxide synthase 3 (endothelial cell)
Aliases ECNOS; eNOS; endothelial nitric oxide synthase; EC-NOS; NOS type III; NOSIII; cNOS; endothelial NOS; nitric ......
Chromosomal Location7q36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane. Membrane, caveola. Cytoplasm, cytoskeleton. Golgi apparatus. Note=Specifically associates with actin cytoskeleton in the G2 phase of the cell cycle; which is favored by interaction with NOSIP and results in a reduced enzymatic activity.
Domain PF00667 FAD binding domain
PF00258 Flavodoxin
PF00175 Oxidoreductase NAD-binding domain
PF02898 Nitric oxide synthase
Function

Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets.; FUNCTION: Isoform eNOS13C: Lacks eNOS activity, dominant-negative form that may down-regulate eNOS activity by forming heterodimers with isoform 1.

> Gene Ontology
 
Biological Process GO:0000302 response to reactive oxygen species
GO:0000303 response to superoxide
GO:0000305 response to oxygen radical
GO:0001525 angiogenesis
GO:0001542 ovulation from ovarian follicle
GO:0001667 ameboidal-type cell migration
GO:0001701 in utero embryonic development
GO:0001974 blood vessel remodeling
GO:0001990 regulation of systemic arterial blood pressure by hormone
GO:0002026 regulation of the force of heart contraction
GO:0002028 regulation of sodium ion transport
GO:0002237 response to molecule of bacterial origin
GO:0003012 muscle system process
GO:0003013 circulatory system process
GO:0003015 heart process
GO:0003018 vascular process in circulatory system
GO:0003044 regulation of systemic arterial blood pressure mediated by a chemical signal
GO:0003057 regulation of the force of heart contraction by chemical signal
GO:0003073 regulation of systemic arterial blood pressure
GO:0003100 regulation of systemic arterial blood pressure by endothelin
GO:0006140 regulation of nucleotide metabolic process
GO:0006164 purine nucleotide biosynthetic process
GO:0006182 cGMP biosynthetic process
GO:0006520 cellular amino acid metabolic process
GO:0006525 arginine metabolic process
GO:0006527 arginine catabolic process
GO:0006801 superoxide metabolic process
GO:0006809 nitric oxide biosynthetic process
GO:0006813 potassium ion transport
GO:0006814 sodium ion transport
GO:0006816 calcium ion transport
GO:0006979 response to oxidative stress
GO:0007263 nitric oxide mediated signal transduction
GO:0007292 female gamete generation
GO:0007548 sex differentiation
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0008015 blood circulation
GO:0008016 regulation of heart contraction
GO:0008217 regulation of blood pressure
GO:0008406 gonad development
GO:0008585 female gonad development
GO:0008625 extrinsic apoptotic signaling pathway via death domain receptors
GO:0009063 cellular amino acid catabolic process
GO:0009064 glutamine family amino acid metabolic process
GO:0009065 glutamine family amino acid catabolic process
GO:0009150 purine ribonucleotide metabolic process
GO:0009152 purine ribonucleotide biosynthetic process
GO:0009165 nucleotide biosynthetic process
GO:0009187 cyclic nucleotide metabolic process
GO:0009190 cyclic nucleotide biosynthetic process
GO:0009260 ribonucleotide biosynthetic process
GO:0009266 response to temperature stimulus
GO:0009408 response to heat
GO:0009636 response to toxic substance
GO:0010035 response to inorganic substance
GO:0010543 regulation of platelet activation
GO:0010544 negative regulation of platelet activation
GO:0010631 epithelial cell migration
GO:0010959 regulation of metal ion transport
GO:0014738 regulation of muscle hyperplasia
GO:0014740 negative regulation of muscle hyperplasia
GO:0014745 negative regulation of muscle adaptation
GO:0014805 smooth muscle adaptation
GO:0014806 smooth muscle hyperplasia
GO:0014900 muscle hyperplasia
GO:0015672 monovalent inorganic cation transport
GO:0016054 organic acid catabolic process
GO:0019430 removal of superoxide radicals
GO:0019932 second-messenger-mediated signaling
GO:0022602 ovulation cycle process
GO:0030168 platelet activation
GO:0030193 regulation of blood coagulation
GO:0030195 negative regulation of blood coagulation
GO:0030323 respiratory tube development
GO:0030324 lung development
GO:0030728 ovulation
GO:0030799 regulation of cyclic nucleotide metabolic process
GO:0030801 positive regulation of cyclic nucleotide metabolic process
GO:0030802 regulation of cyclic nucleotide biosynthetic process
GO:0030804 positive regulation of cyclic nucleotide biosynthetic process
GO:0030808 regulation of nucleotide biosynthetic process
GO:0030810 positive regulation of nucleotide biosynthetic process
GO:0030823 regulation of cGMP metabolic process
GO:0030825 positive regulation of cGMP metabolic process
GO:0030826 regulation of cGMP biosynthetic process
GO:0030828 positive regulation of cGMP biosynthetic process
GO:0031279 regulation of cyclase activity
GO:0031281 positive regulation of cyclase activity
GO:0031282 regulation of guanylate cyclase activity
GO:0031284 positive regulation of guanylate cyclase activity
GO:0031663 lipopolysaccharide-mediated signaling pathway
GO:0032102 negative regulation of response to external stimulus
GO:0032496 response to lipopolysaccharide
GO:0032768 regulation of monooxygenase activity
GO:0034405 response to fluid shear stress
GO:0034599 cellular response to oxidative stress
GO:0034614 cellular response to reactive oxygen species
GO:0035150 regulation of tube size
GO:0042311 vasodilation
GO:0042312 regulation of vasodilation
GO:0042698 ovulation cycle
GO:0043266 regulation of potassium ion transport
GO:0043267 negative regulation of potassium ion transport
GO:0043271 negative regulation of ion transport
GO:0043500 muscle adaptation
GO:0043502 regulation of muscle adaptation
GO:0043542 endothelial cell migration
GO:0044057 regulation of system process
GO:0044282 small molecule catabolic process
GO:0045137 development of primary sexual characteristics
GO:0045454 cell redox homeostasis
GO:0045765 regulation of angiogenesis
GO:0045766 positive regulation of angiogenesis
GO:0045776 negative regulation of blood pressure
GO:0045909 positive regulation of vasodilation
GO:0045981 positive regulation of nucleotide metabolic process
GO:0046068 cGMP metabolic process
GO:0046209 nitric oxide metabolic process
GO:0046390 ribose phosphate biosynthetic process
GO:0046395 carboxylic acid catabolic process
GO:0046545 development of primary female sexual characteristics
GO:0046660 female sex differentiation
GO:0048511 rhythmic process
GO:0048514 blood vessel morphogenesis
GO:0048608 reproductive structure development
GO:0048771 tissue remodeling
GO:0050817 coagulation
GO:0050818 regulation of coagulation
GO:0050819 negative regulation of coagulation
GO:0050865 regulation of cell activation
GO:0050866 negative regulation of cell activation
GO:0050878 regulation of body fluid levels
GO:0050880 regulation of blood vessel size
GO:0050886 endocrine process
GO:0050999 regulation of nitric-oxide synthase activity
GO:0051051 negative regulation of transport
GO:0051339 regulation of lyase activity
GO:0051341 regulation of oxidoreductase activity
GO:0051346 negative regulation of hydrolase activity
GO:0051349 positive regulation of lyase activity
GO:0051924 regulation of calcium ion transport
GO:0051926 negative regulation of calcium ion transport
GO:0052652 cyclic purine nucleotide metabolic process
GO:0060047 heart contraction
GO:0060541 respiratory system development
GO:0061041 regulation of wound healing
GO:0061045 negative regulation of wound healing
GO:0061458 reproductive system development
GO:0070838 divalent metal ion transport
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071396 cellular response to lipid
GO:0071450 cellular response to oxygen radical
GO:0071451 cellular response to superoxide
GO:0072511 divalent inorganic cation transport
GO:0072522 purine-containing compound biosynthetic process
GO:0072593 reactive oxygen species metabolic process
GO:0090066 regulation of anatomical structure size
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:0090257 regulation of muscle system process
GO:0097191 extrinsic apoptotic signaling pathway
GO:0098754 detoxification
GO:0098869 cellular oxidant detoxification
GO:1900046 regulation of hemostasis
GO:1900047 negative regulation of hemostasis
GO:1900371 regulation of purine nucleotide biosynthetic process
GO:1900373 positive regulation of purine nucleotide biosynthetic process
GO:1900542 regulation of purine nucleotide metabolic process
GO:1900544 positive regulation of purine nucleotide metabolic process
GO:1901293 nucleoside phosphate biosynthetic process
GO:1901342 regulation of vasculature development
GO:1901565 organonitrogen compound catabolic process
GO:1901605 alpha-amino acid metabolic process
GO:1901606 alpha-amino acid catabolic process
GO:1902041 regulation of extrinsic apoptotic signaling pathway via death domain receptors
GO:1902042 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors
GO:1903034 regulation of response to wounding
GO:1903035 negative regulation of response to wounding
GO:1903409 reactive oxygen species biosynthetic process
GO:1903522 regulation of blood circulation
GO:1903524 positive regulation of blood circulation
GO:1904018 positive regulation of vasculature development
GO:1990748 cellular detoxification
GO:2001057 reactive nitrogen species metabolic process
GO:2001233 regulation of apoptotic signaling pathway
GO:2001234 negative regulation of apoptotic signaling pathway
GO:2001236 regulation of extrinsic apoptotic signaling pathway
GO:2001237 negative regulation of extrinsic apoptotic signaling pathway
Molecular Function GO:0003779 actin binding
GO:0003785 actin monomer binding
GO:0004497 monooxygenase activity
GO:0004517 nitric-oxide synthase activity
GO:0005506 iron ion binding
GO:0005516 calmodulin binding
GO:0010181 FMN binding
GO:0016597 amino acid binding
GO:0016705 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen
GO:0016709 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen
GO:0020037 heme binding
GO:0031406 carboxylic acid binding
GO:0034617 tetrahydrobiopterin binding
GO:0034618 arginine binding
GO:0043168 anion binding
GO:0046870 cadmium ion binding
GO:0046906 tetrapyrrole binding
GO:0048037 cofactor binding
GO:0050660 flavin adenine dinucleotide binding
GO:0050661 NADP binding
GO:0050662 coenzyme binding
GO:0097110 scaffold protein binding
Cellular Component GO:0005901 caveola
GO:0030139 endocytic vesicle
GO:0030659 cytoplasmic vesicle membrane
GO:0030666 endocytic vesicle membrane
GO:0044853 plasma membrane raft
GO:0045121 membrane raft
GO:0098589 membrane region
GO:0098857 membrane microdomain
> KEGG and Reactome Pathway
 
KEGG hsa04020 Calcium signaling pathway
hsa04022 cGMP-PKG signaling pathway
hsa04066 HIF-1 signaling pathway
hsa04071 Sphingolipid signaling pathway
hsa04151 PI3K-Akt signaling pathway
hsa04370 VEGF signaling pathway
hsa04611 Platelet activation
hsa04915 Estrogen signaling pathway
hsa04921 Oxytocin signaling pathway
hsa00330 Arginine and proline metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-1430728: Metabolism
R-HSA-202131: Metabolism of nitric oxide
R-HSA-203754: NOSIP mediated eNOS trafficking
R-HSA-203641: NOSTRIN mediated eNOS trafficking
R-HSA-392154: Nitric oxide stimulates guanylate cyclase
R-HSA-418346: Platelet homeostasis
R-HSA-1222556: ROS, RNS production in phagocytes
R-HSA-162582: Signal Transduction
R-HSA-194138: Signaling by VEGF
R-HSA-1474151: Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218920: VEGFR2 mediated vascular permeability
R-HSA-203615: eNOS activation
R-HSA-203765: eNOS activation and regulation
Summary
SymbolNOS3
Namenitric oxide synthase 3 (endothelial cell)
Aliases ECNOS; eNOS; endothelial nitric oxide synthase; EC-NOS; NOS type III; NOSIII; cNOS; endothelial NOS; nitric ......
Chromosomal Location7q36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NOS3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between NOS3 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
24259296Lung CarcinomaInhibit immunityThe production of PNT in G-MDSC depended on the expression of gp91(phox) and endothelial NO synthase (eNOS), while inducible NO synthase (iNOS) mediated the generation of NO in Mo-MDSC. Deletion of eNOS and gp91(phox) or scavenging of PNT blocked the suppressive function of G-MDSC and induced anti-tumoral effects, without altering Mo-MDSC inhibitory activity.
Summary
SymbolNOS3
Namenitric oxide synthase 3 (endothelial cell)
Aliases ECNOS; eNOS; endothelial nitric oxide synthase; EC-NOS; NOS type III; NOSIII; cNOS; endothelial NOS; nitric ......
Chromosomal Location7q36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NOS3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolNOS3
Namenitric oxide synthase 3 (endothelial cell)
Aliases ECNOS; eNOS; endothelial nitric oxide synthase; EC-NOS; NOS type III; NOSIII; cNOS; endothelial NOS; nitric ......
Chromosomal Location7q36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NOS3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2290.45
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3630.655
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.130.833
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.060.889
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.6210.741
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.650.784
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2920.436
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0680.927
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.5610.479
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.5320.205
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.0010.245
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2160.086
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NOS3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.41.460.177
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916012.5-12.50.52
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59022.2-22.20.505
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolNOS3
Namenitric oxide synthase 3 (endothelial cell)
Aliases ECNOS; eNOS; endothelial nitric oxide synthase; EC-NOS; NOS type III; NOSIII; cNOS; endothelial NOS; nitric ......
Chromosomal Location7q36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NOS3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNOS3
Namenitric oxide synthase 3 (endothelial cell)
Aliases ECNOS; eNOS; endothelial nitric oxide synthase; EC-NOS; NOS type III; NOSIII; cNOS; endothelial NOS; nitric ......
Chromosomal Location7q36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NOS3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NOS3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNOS3
Namenitric oxide synthase 3 (endothelial cell)
Aliases ECNOS; eNOS; endothelial nitric oxide synthase; EC-NOS; NOS type III; NOSIII; cNOS; endothelial NOS; nitric ......
Chromosomal Location7q36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NOS3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNOS3
Namenitric oxide synthase 3 (endothelial cell)
Aliases ECNOS; eNOS; endothelial nitric oxide synthase; EC-NOS; NOS type III; NOSIII; cNOS; endothelial NOS; nitric ......
Chromosomal Location7q36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NOS3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNOS3
Namenitric oxide synthase 3 (endothelial cell)
Aliases ECNOS; eNOS; endothelial nitric oxide synthase; EC-NOS; NOS type III; NOSIII; cNOS; endothelial NOS; nitric ......
Chromosomal Location7q36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NOS3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNOS3
Namenitric oxide synthase 3 (endothelial cell)
Aliases ECNOS; eNOS; endothelial nitric oxide synthase; EC-NOS; NOS type III; NOSIII; cNOS; endothelial NOS; nitric ......
Chromosomal Location7q36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NOS3 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting NOS3.
ID Name Drug Type Targets #Targets
DB00125L-ArginineSmall MoleculeARG2, ASL, ASS1, AZIN2, NOS2, NOS3, SLC7A1, SLC7A3, SLC7A49
DB00155L-CitrullineSmall MoleculeASS1, DDAH1, DDAH2, NOS1, NOS2, NOS3, OTC, PADI1, PADI2, PADI3, PA ......12
DB00360SapropterinSmall MoleculeNOS3, PAH, TH, TPH14
DB01110MiconazoleSmall MoleculeKCNH2, KCNH6, KCNH7, KCNMA1, KCNMB1, KCNMB2, KCNMB3, KCNMB4, KCNN1 ......15
DB01686N,N-dimethylarginineSmall MoleculeNOS2, NOS32
DB01821L-N(Omega)-Nitroarginine-2,4-L-Diaminobutyric AmideSmall MoleculeNOS1, NOS32
DB01833L-2-Amino-4-(Guanidinooxy)Butyric AcidSmall MoleculeNOS31
DB019973-Bromo-7-NitroindazoleSmall MoleculeNOS1, NOS2, NOS33
DB02027N-{(4s)-4-Amino-5-[(2-Aminoethyl)Amino]Pentyl}-N'-NitroguanidineSmall MoleculeNOS1, NOS32
DB02044N-(3-(Aminomethyl)Benzyl)AcetamidineSmall MoleculeNOS1, NOS2, NOS33
DB020481,2,4-Triazole-CarboxamidineSmall MoleculeNOS31
DB02077L-N(Omega)-Nitroarginine-(4r)-Amino-L-Proline AmideSmall MoleculeNOS1, NOS32
DB02141S,S'-(1,4-Phenylene-Bis(1,2-Ethanediyl))Bis-IsothioureaSmall MoleculeNOS31
DB022077-NitroindazoleSmall MoleculeNOS2, NOS32
DB02234S-EthylisothioureaSmall MoleculeNOS2, NOS32
DB023352-AminothiazolineSmall MoleculeNOS31
DB02589Se-Ethyl-IsoselenoureaSmall MoleculeNOS31
DB029112,4-Diamino-6-Phenyl-5,6,7,8,-TetrahydropteridineSmall MoleculeNOS31
DB02979N1,N14-Bis((S-Methyl)Isothioureido)TetradecaneSmall MoleculeNOS31
DB02994Cacodylic acidSmall MoleculeAKR1B1, GNAT1, NOS33
DB030657-Nitroindazole-2-CarboxamidineSmall MoleculeNOS31
DB031006-NitroindazoleSmall MoleculeNOS2, NOS32
DB03144N-Omega-Hydroxy-L-ArginineSmall MoleculeARG1, NOS1, NOS2, NOS34
DB03305N5-Iminoethyl-L-OrnithineSmall MoleculeNOS31
DB033325,6-Cyclic-TetrahydropteridineSmall MoleculeNOS31
DB03707S-Ethyl-N-Phenyl-IsothioureaSmall MoleculeNOS1, NOS32
DB03910S,S'-(1,3-Phenylene-Bis(1,2-Ethanediyl))Bis-IsothioureaSmall MoleculeNOS31
DB039186S-5,6,7,8-TetrahydrobiopterinSmall MoleculeNOS31
DB03963S-(Dimethylarsenic)CysteineSmall MoleculeCOPG1, NOS3, TLR2, XRCC44
DB03974L-HomoarginineSmall MoleculeNOS31
DB04018S-Isopropyl-IsothioureaSmall MoleculeNOS31
DB04223NitroarginineSmall MoleculeNOS1, NOS32
DB045345-NitroindazoleSmall MoleculeNOS2, NOS32
DB04559N-(Chlorophenyl)-N'-HydroxyguanidineSmall MoleculeNOS31
DB05676ApremilastSmall MoleculeIFNG, IL2, NOS3, PDE4A, PDE4B, PDE4D, TNF7
DB07001(3S,5E)-3-propyl-3,4-dihydrothieno[2,3-f][1,4]oxazepin-5(2H)-imineSmall MoleculeNOS31
DB072445-{4-[(3,5-DIFLUOROBENZYL)AMINO]PHENYL}-6-ETHYLPYRIMIDINE-2,4-DIAMINESmall MoleculeNOS3, REN2
DB07388ETHYL 4-[(4-METHYLPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATESmall MoleculeNOS2, NOS32
DB08018N-{(3S,4S)-4-[(6-AMINO-4-METHYLPYRIDIN-2-YL)METHYL]PYRROLIDIN-3-YL}-N'-(4-CHLOROBENZYL)ETHANE-1,2-DIAMINESmall MoleculeNOS1, NOS32
DB08019N-{(3R,4S)-4-[(6-amino-4-methylpyridin-2-yl)methyl]pyrrolidin-3-yl}-N'-(3-chlorobenzyl)ethane-1,2-diamineSmall MoleculeNOS1, NOS32
DB09237LevamlodipineSmall MoleculeCACNA1C, NOS2, NOS33